Neurotech Files for US Orphan Drug Designation in Rett Syndrome

Neurotech Reports Significant Clinical Benefits and Safety in Phase I/II Rett Syndrome Clinical Trial

All Phase I/II Rett Syndrome Patients to Receive NTI164 Treatment for a Total of 52 Weeks

Neurotech Completes Patient Recruitment in Phase I/II Rett Syndrome Clinical Trial

Neurotech to Launch Phase II Clinical Trial in Rett Syndrome